# DiaMedica Therapeutics Inc.: overview DMAC · Nasdaq · CIK 1401040 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dmac.md) · [Financials](/companies/dmac/financials.md) · [Filings](/companies/dmac/filings.md) · [Insiders](/companies/dmac/insiders.md) Latest reported revenue: [$0](/filings/0001437749-20-005906.md) for Q4 FY2018, three months to 2018-12-31, from the 10-K filed Mar 23, 2020 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-20-005906). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(4,479) d](/filings/0001437749-25-034469.md) | [(6,441) d](/filings/0001437749-26-010342.md) | [(7,161)](/filings/0001437749-26-015220.md) | [(7,604) d](/filings/0001437749-26-026792.md) | [(6,566) d](/filings/0001437749-25-034469.md) | [(7,771) d](/filings/0001437749-26-010342.md) | [(9,090)](/filings/0001437749-26-015220.md) | [(8,117) d](/filings/0001437749-26-026792.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.65)](/filings/0001437749-22-006163.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(12.3)](/filings/0001437749-23-008189.md) | [(11.6)](/filings/0001437749-24-008522.md) | [(18.8)](/filings/0001437749-25-008018.md) | [(22.1)](/filings/0001437749-26-010342.md) | [(29.1)](/filings/0001437749-26-010342.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dmac/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [COOPERMAN LEON G](/funds/898382.md) | 2026-06-30 | $24.3m | 3,450,000 | | Added +1,430,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.9m | 2,252,285 | | Added +396,098 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $6.3m | 894,115 | | Added +113,599 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $6.0m | 845,309 | | Reduced −90,283 | | [PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE](/funds/1047859.md) | 2026-03-31 | $5.9m | 875,000 | | Not compared | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $4.6m | 646,743 | | Added +2,532 | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $2.7m | 382,317 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.5m | 355,523 | | Added +22,067 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $2.4m | 338,107 | | Added +18,432 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $2.3m | 327,518 | | Reduced −11,008 | ## Recent filings [All 426 filings](/companies/dmac/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-10 | 16:37 ET | [10-Q](/filings/0001437749-26-026792.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026792 | | 2026-08-10 | 16:35 ET | [8-K](/filings/0001437749-26-026790.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026790 | | 2026-05-21 | 16:30 ET | [8-K](/filings/0001437749-26-018106.md) | 5.07 Shareholder vote results | 0001437749-26-018106 | | 2026-05-06 | 16:38 ET | [10-Q](/filings/0001437749-26-015220.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015220 | | 2026-05-06 | 16:36 ET | [8-K](/filings/0001437749-26-015218.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-015218 | | 2026-04-01 | 16:06 ET | [DEF 14A](/filings/0001437749-26-010879.md) | Proxy statement, period 2026-05-20 | 0001437749-26-010879 | | 2026-03-31 | 18:40 ET | [8-K](/filings/0001437749-26-010409.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-010409 | | 2026-03-30 | 17:34 ET | [10-K](/filings/0001437749-26-010342.md) | Annual report, period 2025-12-31 | 0001437749-26-010342 | | 2026-01-05 | 09:15 ET | [8-K](/filings/0001437749-26-000175.md) | 8.01 Other events | 0001437749-26-000175 | | 2025-12-18 | 08:45 ET | [8-K](/filings/0001437749-25-038211.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-038211 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010342.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1401040 - Tickers: DMAC - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: Z4 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.